Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma

Annals of Oncology

Volumn 10, Issue 5, 1999, Pages 527-532

  Przepiorka, D ^a,b   Van Besien, K ^a   Khouri, I ^a   Hagemeister, F ^a   Samuels, B ^a   Folloder, J ^a   Ueno, N T ^a   Molldrem, J ^a   Mehra, R ^a   Korbling M ^a   Giralt, S ^a   Gajewski, J ^a   Donato, M ^a   Cleary, K ^a   Claxton, D ^a   Braunschweig, I ^a   Andersson, B ^a   Anderlini, P ^a   Champlin, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Allogeneic transplantation; BEAM; Lymphoma

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; TACROLIMUS;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG TOLERABILITY; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; SURVIVAL; TREATMENT OUTCOME;

EID: 0033044208     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010369     Document Type: Article

References (49)

1. Bierman PJ, Armitage JO. Autologous bone marrow transplantation for non-Hodgkin's lymphoma. In Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Boston, MA: Blackwell Scientific Publications 1994; 683-95.
2. Appelbaum FR, Thomas ED, Buckner CD et al. Treatment of non-Hodgkin's lymphoma with chemoradiotherapy and allogeneic marrow transplantation. Hematol Oncol 1983; 1: 149-57.
3. Phillips GL, Herzig RH, Lazarus HM et al. High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma. J Clin Oncol 1986; 4: 480-8.
4. Appelbaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340-7.
5. Copelan EA, Kapoor N, Gibbins B et al. Allogeneic marrow transplantation in non-Hodgkin's lymphoma. BMT 1990; 5: 47-50.
6. Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graftversus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-53.
7. Lundberg JH, Hansen RM, Chitambar CR et al. Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. J Clin Oncol 1991; 9: 1848-59.
8. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10: 1690-5.
9. Shepherd JD, Barnett MJ, Connors JM et al. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma. BMT 1993; 12: 591-6.
10. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-5.
11. Mendoza E, Territo M, Schiller G et al. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. BMT 1995; 15: 299-303.
12. Demirer T, Weaver CH, Buckner CD et al. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol 1995; 13: 596-602.
13. van Besien KW, Khouri IF, Giralt SA et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. J Clin Oncol 1995; 13: 1096-102.
14. van Besien KW, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology. Am J Med 1996; 100: 299-307.
15. Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. BMT 1997; 20: 369-74.
16. van Besien K, Thall P, Korbling M et al. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: Experience in 44 consecutive patients. Biol Blood Marrow Transplant 1997; 3: 150-6.
17. Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201-5.
18. Juckett M, Rowlings P, Hessner M et al. T-cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: Clinical and molecular follow-up. BMT 1998; 21: 893-9.
19. Mandigers CMPW, Raemaekers JMM, Schattenberg AVMB et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. Br J Haematol 1998; 100: 198-206.
20. Biron P, Goldstone A, Colombat P et al. A Phase II study of a new cytoreductive conditioning regimen with autologous bone marrow transplantation for lymphoma: The BEAM protocol. In Dicke KA, Spitzer G, Zander AR (eds): Proceedings of the Third International Symposium for Autologous Transplantation. 1987; 593-600.
21. Gribben JG, Goldstone AH, Linch DC et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. J Clin Oncol 1989; 7: 1621-9.
22. Colombat PH, Biron P, Laporte JP et al. BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas. Eur J Cancer 1990; 26: 858.
23. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-95.
24. Caballero MD, Rubio V, Rifon J et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors. BMT 1997; 20: 451-8.
25. Rossi A, Cortelazzo R, Bellavita P et al. Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma. Br J Haematol 1997; 96: 620-6.
26. Mills W, Strang J, Goldstone AH et al. Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leuk Lymph 1995; 17: 263-70.
27. Vitolo U, Cortellazzo S, Liberati AM et al. Intensified and highdose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol 1997; 15: 491-8.
28. Cortelazzo S, Rossi A, Viero P et al. BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as frontline therapy for high-risk patients with diffuse large-cell lymphoma. Br J Haematol 1997; 99: 379-85.
29. Gassman W, Uharek L, Erbersdobler A et al. High-dose cytostatic agents in allogeneic bone marrow transplantation: Comparison of the engraftment promoting potential. Br J Haematol 1991; 78: 310-8.
30. Singhal S, Powles R, Treleaven J et al. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: Alloengraftment with potential preservation of fertility in women. BMT 1996; 18: 1049-55.
31. Vey N, De Prijck B, Faucher C et al. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies. BMT 1996; 18: 495-9.
32. van Besien K, Demuynck H, Lemaistre CF et al. High-dose melphalan allows durable engraftment of allogeneic bone marrow. BMT 1995; 15: 321-3.
33. Anderlini P, Przepiorka D, Seong C et al. Factors affecting mobilization of CD34+ cells in normal donors treated with fllgrastim. Transfusion 1997; 37: 507-22.
34. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and minidose methotrexate for prevention of acute graft-vs.-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383-9.
35. Przepiorka D, Anderlini P, Ippoliti C et al. Allogeneic blood stem-cell transplantation in advanced hematologic cancers. BMT 1997; 19: 455-60.
36. Poppema S. Lymphoma classification proposal. Blood 1996; 87: 412-3.
37. Shipp MA, Harrington DP, Anderson JR et al. A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-94.
38. Rodriguez J, Cabanillas F, McLaughlin P et al. A proposal for a simple staging system for intermediate-grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol 1992; 3: 711-7.
39. Yam P, Petz LD, Ali S et al. Development of a single probe for documentation of chimerism following bone marrow transplantation. Am J Hum Genet 1987; 41: 867-81.
40. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-8.
41. Przepiorka D, Weisdorf D, Martin P et al. Report of the 1994 consensus conference on acute GVHD grading. BMT 1995; 15: 825-8.
42. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
43. Bearman SI, Appelbaum FR, Back A et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288-94.
44. Jules-Elysee K, Stover DE, Yahalom J et al. Pulmonary complications in lymphoma patients treated with high-dose therapy and autologous bone marrow transplantation. Am Rev Resp Dis 1992; 146: 485-91.
45. Salloum E, Jillella AP, Nadkarni R et al. Assessment of pulmonary and cardiac function after high-dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer 1998; 82: 1506-12.
46. van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832-6.
47. de Lima M, van Besien KW, Giralt SA et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. BMT 1997; 19: 121-7.
48. Tsai T, Goodman S, Saez R et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. BMT 1997; 20: 859-63.
49. Pedersen-Bjergaard J, Pedersen M, Myhre J et al. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem-cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia 1997; 11: 1654-60.